Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, December 1, 2020

#MedicalTech/ #TherapeuticTechnology #Stock News -Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines from Human Blood Plasma; @Sigyn_inc

 

#MedicalTech/ #TherapeuticTechnology #Stock News -Sigyn Therapeutics (OTC: $SIGY) Reports Simultaneous Clearance of Endotoxin and Inflammatory Cytokines from Human Blood Plasma; @Sigyn_inc

 

Sigyn Therapy™ is a Candidate to Treat Sepsis and Other Life-Threatening Inflammatory Conditions That Are Not Addressed with Approved Drugs

 


SAN DIEGO, CA, December 1, 2020 / -(Investorideas.com newswire) Breaking Medical Tech/ therapeutic technology stock news -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on treating life-threatening inflammatory conditions, today announced the completion of an in vitro study that demonstrated the ability of Sigyn Therapy™ to clear both endotoxin and inflammatory cytokines from human blood plasma. 

 

Read this news featuring SIGY in full at https://www.investorideas.com/news/2020/biotech/12011SIGY-Endotoxin-Cytokines.asp

 

Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome, which precipitates a wide-range of life-threatening conditions, including sepsis, the most common cause of hospital deaths.  Virus induced cytokine storm syndrome is associated with high mortality and currently is a leading cause of SARS-CoV-2 (COVID-19) deaths.  Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines located in hospitals and clinics worldwide.

 

In the in vitro study, Sigyn Therapy simultaneously reduced the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  The resulting data will be incorporated into an Investigational Device Exemption (IDE) that Sigyn plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

“The simultaneous clearance of endotoxin and inflammatory cytokines is a significant milestone that reinforces the potential of Sigyn Therapy to overcome the limitations of industry pioneering devices that are currently deployed to treat life-threatening inflammatory conditions,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics.

 

At present, the CytoSorb device from CytoSorbents Corporation and the Toraymyxin device from Toray Industries are market cleared and broadly administered to treat a wide-range of life-threatening inflammatory conditions outside of the United States. In regards to mechanism, the Toraymyxin device has a high specificity to bind circulating endotoxin, but does not address inflammatory cytokines. Conversely, the CytoSorb device depletes inflammatory cytokines from circulation, but does not address endotoxin.

 

In addition to reporting the dual clearance of endotoxin and inflammatory cytokines, the Company further disclosed that it plans to evaluate the ability of Sigyn Therapy to address other inflammatory targets, including CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream.  The Company believes that Sigyn Therapy is the first therapeutic candidate to target circulating CytoVesicles.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring (OTCMARKETS: SIGY) is a paid for news release on Investorideas.com  https://www.investorideas.com/News-Upload/ More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 



BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com

 

 

 

 

 

Friday, November 20, 2020

New #Stocks to Watch at Investor Ideas – Biotech (NasdaqGS: $ECOR), Tech (NasdaqGS: $PFMT), CyberSecurity (NYSE American: $CTEK) and Homebuilder (TSXV: $CVX.V)

 New #Stocks to Watch at Investor Ideas – Biotech (NasdaqGS: $ECOR), Tech (NasdaqGS: $PFMT), CyberSecurity (NYSE American: $CTEK) and Homebuilder (TSXV: $CVX.V)

 


 

Point Roberts WA, Delta BC, November 20, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch. Today’s stocks in Biotech, Tech, CyberSecurity and Homebuilder have been added to our list of free stock directories in each sector.

 

Read this in full at

https://www.investorideas.com/news/2020/main/11201Stocks.asp

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

The newest biotech companies are involved in spectroscopy, bioelectronic medicine and telemedicine.

 

Added to the tech directory are a fintech, an electronic components and a consumer privacy company.

 

The newest cybersecurity companies work in healthcare privacy and cloud security.

 

The latest homebuilder companies are involved in smart-glass windows and concrete products, respectively.

 

New Stocks added to Biotech stocks directory:

Know Labs, Inc. (OTC:KNWN) technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company's first product will be the non-invasive UBAND™ Continuous Glucose Monitor (CGM)

 

electroCore (NasdaqGS:ECOR) is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

 

Conversion Labs (OTC:CVLB) is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S.

 

New Stocks added to Tech stocks directory:

Performant Financial Corp. (NasdaqGS:PFMT) helps government and commercial organizations enhance revenue and contain costs by preventing, identifying and recovering waste, improper payments and defaulted assets. Performant is a leading provider of these services in several industries, including healthcare, student loans and government. Performant has been providing recovery audit services for over ten years to both commercial and government clients, including serving as a Recovery Auditor for the Centers for Medicare and Medicaid Services. Powered by a proprietary analytic platform and workflow technology, Performant also provides professional services related to the recovery effort, including reporting capabilities, support services, customer care and stakeholder training programs meant to mitigate future instances of improper payments.

 

Killi Ltd. (TSXV:MYID) is a consumer privacy ecosystem that allows consumers to take back control of their consumer data from those who have been collecting it and selling it unbeknownst to them. Killi is currently available online or via iOS or Android in five countries (US, Canada, Singapore, Australia, and New Zealand). Killi pays users automatically every week a cash Data Dividend™ for the use of their data, making Killi the only company in the world that is fairly compensating users for the purchase of their data. Killi is also the creator of uaretheproduct.io, a consumer-facing website that allows consumers to determine their data's value broken out by individual platform.

 

Converge Technology Solutions (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical, telecommunications/IT, and transportation markets.CTS’s products for the defense and aerospace markets support increasing threat detection needs, expanding covert surveillance capabilities, remote vehicle capabilities (which require power and weight reductions) and military communications. Specific applications include sonobuoys, hydrophones for sonar, torpedo target acquisition and missile control communications.

 

New Stocks added to CyberSecurity stocks directory:

CynergisTek, Inc. (NYSE American:CTEK) is a top-ranked cybersecurity firm dedicated to serving the information assurance needs of the healthcare industry. CynergisTek offers specialized services and solutions to help organizations achieve privacy, security, and compliance goals. Since 2004, the company has served as a partner to hundreds of healthcare organizations and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been recognized by KLAS as a top performing firm in healthcare cybersecurity and was awarded the 2019 Top Healthcare Cybersecurity Consultants in Black Book IT Advisory Outcomes Survey.

 

Data443 Risk Mitigation (OTC:ATDS) is the de facto industry leader in Data Privacy Solutions for All Things Data Security™, providing software and services to enable secure data across local devices, network, cloud, and databases, at rest and in flight. Its suite of products and services is highlighted by: (i) ARALOC™, which is a market leading secure, cloud-based platform for the management, protection and distribution of digital content to the desktop and mobile devices, which protects an organization’s confidential content and intellectual property assets from leakage — malicious or accidental — without impacting collaboration between all stakeholders; (ii) DataExpress®, the leading data transport, transformation and delivery product trusted by leading financial organizations worldwide; (iii) ArcMail™, which is a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions; (iv) ClassiDocs® the Company’s award-winning data classification and governance technology, which supports CCPA, LGPD, and GDPR compliance; (v) ClassiDocs® for Blockchain, which provides an active implementation for the Ripple XRP that protects blockchain transactions from inadvertent disclosure and data leaks; (vi) Data443® Global Privacy Manager, the privacy compliance and consumer loss mitigation platform which is integrated with ClassiDocs® to do the delivery portions of GDPR and CPRA (previously, CCPA) as well as process Data Privacy Access Requests – removal request – with inventory by ClassiDocs™; (vii) Resilient AccessTM, which enables fine-grained access controls across myriad platforms at scale for internal client systems and commercial public cloud platforms like Salesforce, Box.Net, Google G Suite, Microsoft OneDrive and others; viii) Data443™ Chat History Scanner, which scans chat messages for Compliance, Security, PII, PI, PCI & custom keywords; (ix) the CPRA Framework WordPress plugin, which enables organizations of all sizes to comply with the CPRA privacy framework; (x) FileFacets™, a Software-as-a-Service (SaaS) platform that performs sophisticated data discovery and content search of structured and unstructured data within corporate networks, servers, content management systems, email, desktops and laptops; and (xi) the GDPR Framework WordPress plugin, with over 30,000 active users and over 400,000 downloads it enables organizations of all sizes to comply with the GDPR and other privacy frameworks.

 

New Stocks added to Homebuilder stocks directory:

Crown ElectroKinetics (OTC:CRKN) a global leader in DynamicTint - We Make Your Glass Smarter™. Originally invented by Hewlett-Packard (HP, Inc.), our technology allows any glass surface to transition between clear and dark in seconds. DynamicTint™ allows windows to transition from transparent to black. With applications to a wide array of windows, including commercial buildings, automotive sunroofs, and residential skylights, Crown partners with leading glass and film manufacturers for mass production and distribution. At the core of Crown's technology is a thin film that is powered by electrically-charged pigment which not only replaces common window tints but is also a more sustainable alternative to traditional window treatments

 

CEMATRIX Corporation (TSXV:CVX) is a rapidly growing, cash flow positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through recent acquisitions of Chicago based MixOnSite and Bellingham based Pacific International Grout, CEMATRIX is now North America’s largest Cellular Concrete company.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto CornerPlay by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate ChangeExploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 



 

 

 

 

 

 

 

 

#Medtech #Stocks in the News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT

 

#Medtech #Stocks in the News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT

 

SCOTTSDALE, AZ, November 20, 2020 (Investorideas.com Newswire) – Breaking Medical Technology stock news - Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared WellnessPro+ device, representing approximately $4.2 million of inventory to meet demand.

 

Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11201Electromedical-Technologies-EMED.asp

 

The Company began production in September and has fully paid for and completed its first phase of inventory buildup in order to meet rising demand as we transition into 2021. We want to make sure that we do not run out of inventory which occurred in the first quarter of this year.

 

Matthew Wolfson, Founder and CEO of EMED, commented, “Every day more doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. The reason for the increase in demand is that more and more people are realizing that there are other powerful treatment options such as bioelectronics, that does not include injections, invasive procedures or opioids that have the possibility of harmful side effects such as addiction and death.”

 

Commenting further, Mr. Wolfson said, “This inventory increase fits perfectly with our strategic plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.”  (https://electromedtech.com/register/)

 

Finally commenting, Mr. Wolfson said, “In the world we live in today, people cannot afford the risks associated with opioid-based drugs, but they need results. Word of mouth has been a very valuable marketing tool because our device delivers a powerful solution to chronic pain without any dangerous or harmful side effects. The Wellness Pro produces real results so people can live pain free and get their lives back!”

 

About Electromedical Technologies

Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

 

Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare.  The United States Food and Drug Administration has not reviewed or approved our animal research studies

 

For more information, visit www.electromedtech.com.

 

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

 

Corporate Contact:

Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Electromedical Technologies, Inc. (OTCQB: EMED)  is a paid for news release on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

Thursday, November 19, 2020

#MedicalTechnology #Stock News - Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT

 

#MedicalTechnology #Stock News - Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand; @ElectromedicalT

 

Company completes production of 1,200_FDA-cleared WellnessPro+ devices

 

Inventory build completed ahead of on-boarding new medical practitioners and distributors

 

Demand driven by pain sufferers desire to find non-invasive alternatives 

 


SCOTTSDALE, AZ, November 19, 2020 (Investorideas.com Newswire) – Breaking Medical Technology stock news - Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared WellnessPro+ device, representing approximately $4.2 million of inventory to meet demand.

 

Read this news featuring EMED in full at https://www.investorideas.com/news/2020/biotech/11191EMED-Device-Inventory.asp

 

The Company began production in September and has fully paid for and completed its first phase of inventory buildup in order to meet rising demand as we transition into 2021. We want to make sure that we do not run out of inventory which occurred in the first quarter of this year.

 

Matthew Wolfson, Founder and CEO of EMED, commented, “Every day more doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. The reason for the increase in demand is that more and more people are realizing that there are other powerful treatment options such as bioelectronics, that does not include injections, invasive procedures or opioids that have the possibility of harmful side effects such as addiction and death.”

 

Commenting further, Mr. Wolfson said, “This inventory increase fits perfectly with our strategic plan of engaging and onboarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team.”  (https://electromedtech.com/register/)

 

Finally commenting, Mr. Wolfson said, “In the world we live in today, people cannot afford the risks associated with opioid-based drugs, but they need results. Word of mouth has been a very valuable marketing tool because our device delivers a powerful solution to chronic pain without any dangerous or harmful side effects. The Wellness Pro produces real results so people can live pain free and get their lives back!”

 

About Electromedical Technologies

Headquartered in Scottsdale Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

 

Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare.  The United States Food and Drug Administration has not reviewed or approved our animal research studies

 

For more information, visit www.electromedtech.com.

 

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

 

Corporate Contact:

Electromedical Technologies, Inc.
Matthew Wolfson
Tel: 1.888.880.7888
email:
ceo@electromedtech.com
https://electromedtech.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Electromedical Technologies, Inc. (OTCQB: EMED)  is a paid for news release on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 


BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks